Geron (GERN) Trading Down 7.7%

Geron Co. (NASDAQ:GERN)’s share price was down 7.7% during mid-day trading on Friday . The stock traded as low as $1.68 and last traded at $1.69. Approximately 4,431,393 shares were traded during trading, an increase of 34% from the average daily volume of 3,303,507 shares. The stock had previously closed at $1.83.

Several equities analysts have issued reports on GERN shares. BidaskClub upgraded shares of Geron from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. Zacks Investment Research upgraded shares of Geron from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 4th. BTIG Research started coverage on shares of Geron in a research note on Tuesday, February 12th. They set a “buy” rating and a $4.00 target price on the stock. B. Riley upgraded shares of Geron from a “neutral” rating to a “buy” rating and upped their target price for the company from $1.50 to $3.25 in a research note on Thursday, January 31st. Finally, ValuEngine upgraded shares of Geron from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Geron currently has an average rating of “Buy” and a consensus target price of $3.39.

The company has a market cap of $315.00 million, a PE ratio of -10.56 and a beta of 2.94.



Geron (NASDAQ:GERN) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05). The business had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.22 million. Geron had a negative net margin of 2,534.43% and a negative return on equity of 17.61%. On average, research analysts expect that Geron Co. will post -0.34 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. purchased a new stake in shares of Geron during the 3rd quarter valued at about $214,000. BlackRock Inc. increased its position in shares of Geron by 4.1% during the 3rd quarter. BlackRock Inc. now owns 13,935,757 shares of the biopharmaceutical company’s stock valued at $24,526,000 after purchasing an additional 546,779 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Geron during the 3rd quarter valued at about $100,000. MetLife Investment Advisors LLC increased its position in shares of Geron by 50.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 117,168 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 39,095 shares during the last quarter. Finally, M Holdings Securities Inc. increased its position in shares of Geron by 230.6% during the 3rd quarter. M Holdings Securities Inc. now owns 82,650 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 57,650 shares during the last quarter. Institutional investors and hedge funds own 33.54% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://dakotafinancialnews.com/2019/03/24/geron-gern-trading-down-7-7.html.

Geron Company Profile (NASDAQ:GERN)

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Article: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.